Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

DEAR DR. ROACH: I am a 76-year-old male who is in relatively good health. For the past six months, I have been experiencing diarrhea on and off. I initially spoke to my general physician, and he ...

The plant-focused portfolio diet has been shown to reduce the risks of cardiovascular disease. Here’s how it works. By Caroline Hopkins Legaspi Dr. David Jenkins, a professor of nutritional sciences ...

ATLANTA -- Mortality rates from Clostridioides difficile-related infections have fallen steadily since 2016, but the condition continues to take an uneven lethal toll based on sex, demographics, and ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

Clostridiumdifficile infection (also known as C. diff or CDI) is one of the most common hospital-acquired infections and is a frequent cause of death among hospitalized older adults. Keystone ...

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, and kills up to 30,000. It is a ...

C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive system. It is one of the most common causes of diarrhea linked to ...

TUESDAY, August 5, 2025 (HealthDay News) — C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive system. It is one of the most ...

Please provide your email address to receive an email when new articles are posted on . Ninety-five percent of patients achieved treatment success at 8 weeks after administration of Rebyota via ...

The bacterium Clostridium difficile — otherwise known as C. diff — spreads within intensive care units more than three times as much as previously thought, according to a study published on April 4 in ...